Premenstrual Syndrome Treatment Market by Drug Type (Analgesics, Antidepressants, Oral Contraceptives & Ovarian Suppression Agents, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, by 2027
The premenstrual syndrome (PMS) treatment market refers to the market for products and therapies aimed at alleviating the symptoms associated with premenstrual syndrome. PMS is a common condition that affects women of reproductive age, typically occurring in the days or weeks leading up to menstruation. It is characterized by a range of physical and emotional symptoms, including mood swings, bloating, fatigue, irritability, and breast tenderness. Premenstrual Syndrome Treatment is likely to grow at a rate of 3.9% CAGR by 2027.
Premenstrual Syndrome Treatment Market, By Drug Type
Analgesics
Antidepressants
Oral Contraceptives & Ovarian Suppression Agents Premenstrual Syndrome Treatment Market, By Type
Prescription
OTC
Premenstrual Syndrome Treatment Market, By Distribution Channel
Hospital pharmacies
Drug stores & retail pharmacies
Online providers
Premenstrual Syndrome Treatment Market By Geography
North America
Europe
Asia Pacific
Rest of the World
Here is an overview of the key aspects of the PMS treatment market:
On the basis of product type, the market is divided into Analgesics, Antidepressants and Oral Contraceptives & Ovarian Suppression Agents. The modified silicone fluid has the highest share in the market. This is due to the increased adoption of analgesics as first line treatment for the management of PMS.
The type segment is bifurcated into prescription and OTC where OTC segment holds the significant share in the market. Since, the most of the consumers prefer OTC medicines to relief pain.
As per the distribution channel, the market is classified into Hospital pharmacies, Drug stores & retail pharmacies and Online providers. The online providers segment is likely to show major growth due to the increase in online purchases.
Medications: Various over-the-counter and prescription medications are available to manage PMS symptoms. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, can help relieve pain, cramping, and inflammation. Selective serotonin reuptake inhibitors (SSRIs), typically used as antidepressants, may also be prescribed to regulate mood and reduce emotional symptoms associated with PMS.
Hormonal Therapies: Hormonal therapies are sometimes used to address hormonal imbalances which contribute to PMS symptoms. Oral contraceptives, containing a combination of estrogen and progestin, can help regulate hormone levels and alleviate symptoms. Other hormonal treatments, such as gonadotropin-releasing hormone (GnRH) agonists or antagonists, may be considered in severe cases.
Nutritional Supplements: Certain dietary supplements and natural remedies are used to manage PMS symptoms. These may include calcium, magnesium, vitamin B6, and herbal supplements like chasteberry (vitex agnus-castus), evening primrose oil, or black cohosh. However, the scientific evidence supporting the effectiveness of these supplements in relieving PMS symptoms is mixed.
Lifestyle Changes: Lifestyle modifications can play a significant role in managing PMS symptoms. Regular exercise, a balanced diet, stress reduction techniques, and adequate sleep are commonly recommended. Avoiding caffeine, alcohol, and salty foods may also help reduce symptoms such as bloating and breast tenderness.
Psychological Support: Psychological support, such as cognitive-behavioral therapy (CBT) or counseling, can be beneficial for managing emotional symptoms associated with PMS. These therapies help individuals develop coping strategies, improve mood regulation, and address any underlying psychological factors contributing to PMS symptoms.
Market Trends: The PMS treatment market is witnessing a growing demand for personalized and holistic approaches. There is increasing interest in natural and integrative therapies, including herbal remedies and mind-body techniques. Additionally, advancements in technology have facilitated the development of mobile applications and wearable devices that help individuals track their symptoms, identify patterns, and manage their condition more effectively.
It's important to note that the effectiveness of PMS treatments can vary among individuals, and what works for one person may not work for another. It is recommended that individuals consult with healthcare professionals to discuss their symptoms and determine the most appropriate treatment options for their specific need.
The leading players of the market are ABBVIE INC., AstraZeneca plc, BASF Corporation, Bayer AG., Dr. Reddy’s Laboratories Ltd, Eli Lilly And Company., GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., Shionogi Inc.
High cost of newer herpes zoster vaccines, limiting their accessibility and affordability.
The report analyzes the geographical highlights in terms of consumption of the product/service within the region also indicates the factors which are affecting the market within each
Premenstrual Syndrome Treatment Market, By Drug Type
Analgesics
Antidepressants
Oral Contraceptives & Ovarian Suppression Agents Premenstrual Syndrome Treatment Market, By Type
Prescription
OTC
Premenstrual Syndrome Treatment Market, By Distribution Channel
Hospital pharmacies
Drug stores & retail pharmacies
Online providers
Premenstrual Syndrome Treatment Market By Geography
North America
Europe
Asia Pacific
Rest of the World
Here is an overview of the key aspects of the PMS treatment market:
On the basis of product type, the market is divided into Analgesics, Antidepressants and Oral Contraceptives & Ovarian Suppression Agents. The modified silicone fluid has the highest share in the market. This is due to the increased adoption of analgesics as first line treatment for the management of PMS.
The type segment is bifurcated into prescription and OTC where OTC segment holds the significant share in the market. Since, the most of the consumers prefer OTC medicines to relief pain.
As per the distribution channel, the market is classified into Hospital pharmacies, Drug stores & retail pharmacies and Online providers. The online providers segment is likely to show major growth due to the increase in online purchases.
Medications: Various over-the-counter and prescription medications are available to manage PMS symptoms. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, can help relieve pain, cramping, and inflammation. Selective serotonin reuptake inhibitors (SSRIs), typically used as antidepressants, may also be prescribed to regulate mood and reduce emotional symptoms associated with PMS.
Hormonal Therapies: Hormonal therapies are sometimes used to address hormonal imbalances which contribute to PMS symptoms. Oral contraceptives, containing a combination of estrogen and progestin, can help regulate hormone levels and alleviate symptoms. Other hormonal treatments, such as gonadotropin-releasing hormone (GnRH) agonists or antagonists, may be considered in severe cases.
Nutritional Supplements: Certain dietary supplements and natural remedies are used to manage PMS symptoms. These may include calcium, magnesium, vitamin B6, and herbal supplements like chasteberry (vitex agnus-castus), evening primrose oil, or black cohosh. However, the scientific evidence supporting the effectiveness of these supplements in relieving PMS symptoms is mixed.
Lifestyle Changes: Lifestyle modifications can play a significant role in managing PMS symptoms. Regular exercise, a balanced diet, stress reduction techniques, and adequate sleep are commonly recommended. Avoiding caffeine, alcohol, and salty foods may also help reduce symptoms such as bloating and breast tenderness.
Psychological Support: Psychological support, such as cognitive-behavioral therapy (CBT) or counseling, can be beneficial for managing emotional symptoms associated with PMS. These therapies help individuals develop coping strategies, improve mood regulation, and address any underlying psychological factors contributing to PMS symptoms.
Market Trends: The PMS treatment market is witnessing a growing demand for personalized and holistic approaches. There is increasing interest in natural and integrative therapies, including herbal remedies and mind-body techniques. Additionally, advancements in technology have facilitated the development of mobile applications and wearable devices that help individuals track their symptoms, identify patterns, and manage their condition more effectively.
It's important to note that the effectiveness of PMS treatments can vary among individuals, and what works for one person may not work for another. It is recommended that individuals consult with healthcare professionals to discuss their symptoms and determine the most appropriate treatment options for their specific need.
The leading players of the market are ABBVIE INC., AstraZeneca plc, BASF Corporation, Bayer AG., Dr. Reddy’s Laboratories Ltd, Eli Lilly And Company., GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc., Shionogi Inc.
High cost of newer herpes zoster vaccines, limiting their accessibility and affordability.
The report analyzes the geographical highlights in terms of consumption of the product/service within the region also indicates the factors which are affecting the market within each
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DRUG TYPE: MARKET SIZE & ANALYSIS
5.1. Analgesics
5.2. Antidepressants
5.3. Oral Contraceptives & Ovarian Suppression Agents
6. TYPE: MARKET SIZE & ANALYSIS
6.1. Prescription
6.2. OTC
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Hospital Pharmacies
7.2. Drug Stores & Retail Pharmacies
7.3. Online pharmacies
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. AbbVie INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. AstraZeneca plc.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Bayer AG
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. BASF Corporation
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Dr. Reddy’s Laboratories Ltd
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Eli Lilly And Company
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. GlaxoSmithKline Plc
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. H. Lundbeck A/S
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer Inc
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Shionogi Inc.
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DRUG TYPE: MARKET SIZE & ANALYSIS
5.1. Analgesics
5.2. Antidepressants
5.3. Oral Contraceptives & Ovarian Suppression Agents
6. TYPE: MARKET SIZE & ANALYSIS
6.1. Prescription
6.2. OTC
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Hospital Pharmacies
7.2. Drug Stores & Retail Pharmacies
7.3. Online pharmacies
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. AbbVie INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. AstraZeneca plc.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Bayer AG
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. BASF Corporation
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Dr. Reddy’s Laboratories Ltd
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Eli Lilly And Company
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. GlaxoSmithKline Plc
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. H. Lundbeck A/S
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer Inc
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Shionogi Inc.
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2026 (USD BILLION)
TABLE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR ANALGESICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR ANTIDEPRESSANTS., BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR SURGERIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR PRESCRIPTION, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR OTC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR DRUG STORES & RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR ONLINE PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. U.SPREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.SPREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. U.S PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 20. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 22. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL,2021-2027 (USD BILLION)
TABLE 27. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 30. U.K PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. U.K PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 33. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 39. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. ROE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 44. ROE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 49. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 52. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 55. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 64. ABBVIE INC.: FINANCIALS
TABLE 65. ABBVIE INC: PRODUCTS & SERVICES
TABLE 66. ABBVIE INC: RECENT DEVELOPMENTS
TABLE 67. ASTRAZENECA PLC: FINANCIALS
TABLE 68. ASTRAZENECA PLC: PRODUCTS & SERVICES
TABLE 69. ASTRAZENECA PLC: RECENT DEVELOPMENTS
TABLE 70. BAYER AG: FINANCIALS
TABLE 71. BAYER AG: PRODUCTS & SERVICES
TABLE 72. BAYER AG: RECENT DEVELOPMENTS
TABLE 73. BASF CORPORATION: FINANCIALS
TABLE 74. BASF CORPORATION: PRODUCTS & SERVICES
TABLE 75. BASF CORPORATION: RECENT DEVELOPMENTS
TABLE 76. DR. REDDY’S LABORATORIES LTD: FINANCIALS
TABLE 77. DR. REDDY’S LABORATORIES LTD: PRODUCTS & SERVICES
TABLE 78. DR. REDDY’S LABORATORIES LTD: RECENT DEVELOPMENTS
TABLE 79. ELI LILLY AND COMPANY: FINANCIALS
TABLE 80. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 81. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 82. PFIZER INC: FINANCIALS
TABLE 83. PFIZER INC: PRODUCTS & SERVICES
TABLE 84. PFIZER INC: RECENT DEVELOPMENTS
TABLE 85. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 86. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 87. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 88. H. LUNDBECK A/S: FINANCIALS
TABLE 89. H. LUNDBECK A/S: PRODUCTS & SERVICES
TABLE 90. H. LUNDBECK A/S: RECENT DEVELOPMENTS
TABLE 91. SHIONOGI INC.: FINANCIALS
TABLE 92. SHIONOGI INC: PRODUCTS & SERVICES
TABLE 93. SHIONOGI INC: RECENT DEVELOPMENTS
TABLE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2026 (USD BILLION)
TABLE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR ANALGESICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR ANTIDEPRESSANTS., BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR SURGERIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR PRESCRIPTION, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR OTC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR DRUG STORES & RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE FOR ONLINE PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. U.SPREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.SPREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 19. U.S PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 20. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 22. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 26. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL,2021-2027 (USD BILLION)
TABLE 27. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 29. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 30. U.K PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 32. U.K PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 33. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 35. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 38. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 39. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 41. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. ROE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 44. ROE PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 49. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 51. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 52. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 54. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 55. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 57. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD PREMENSTRUAL SYNDROME TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 64. ABBVIE INC.: FINANCIALS
TABLE 65. ABBVIE INC: PRODUCTS & SERVICES
TABLE 66. ABBVIE INC: RECENT DEVELOPMENTS
TABLE 67. ASTRAZENECA PLC: FINANCIALS
TABLE 68. ASTRAZENECA PLC: PRODUCTS & SERVICES
TABLE 69. ASTRAZENECA PLC: RECENT DEVELOPMENTS
TABLE 70. BAYER AG: FINANCIALS
TABLE 71. BAYER AG: PRODUCTS & SERVICES
TABLE 72. BAYER AG: RECENT DEVELOPMENTS
TABLE 73. BASF CORPORATION: FINANCIALS
TABLE 74. BASF CORPORATION: PRODUCTS & SERVICES
TABLE 75. BASF CORPORATION: RECENT DEVELOPMENTS
TABLE 76. DR. REDDY’S LABORATORIES LTD: FINANCIALS
TABLE 77. DR. REDDY’S LABORATORIES LTD: PRODUCTS & SERVICES
TABLE 78. DR. REDDY’S LABORATORIES LTD: RECENT DEVELOPMENTS
TABLE 79. ELI LILLY AND COMPANY: FINANCIALS
TABLE 80. ELI LILLY AND COMPANY: PRODUCTS & SERVICES
TABLE 81. ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
TABLE 82. PFIZER INC: FINANCIALS
TABLE 83. PFIZER INC: PRODUCTS & SERVICES
TABLE 84. PFIZER INC: RECENT DEVELOPMENTS
TABLE 85. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 86. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 87. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 88. H. LUNDBECK A/S: FINANCIALS
TABLE 89. H. LUNDBECK A/S: PRODUCTS & SERVICES
TABLE 90. H. LUNDBECK A/S: RECENT DEVELOPMENTS
TABLE 91. SHIONOGI INC.: FINANCIALS
TABLE 92. SHIONOGI INC: PRODUCTS & SERVICES
TABLE 93. SHIONOGI INC: RECENT DEVELOPMENTS
